Form 4: Unicycive Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, reports acquisition of stock options.
Summary
- On April 15, 2024, Douglas Jermasek, the EVP of Corporate Strategy at Unicycive Therapeutics, acquired 463,250 stock options at an exercise price of $1.14.
- These options vest over time, with 115,813 vesting on the first anniversary of the grant date and the remaining options vesting monthly over the subsequent 36 months.
- Following this transaction, Jermasek directly owns 1,973,250 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, buy or sell their company's securities. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of stock options by a company executive can be viewed by stakeholders as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of stock options transaction |
| 04/15/2024 | Date stock options exercisable |
| 04/15/2034 | Expiration date of stock options |
| 04/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.